2025 Q4 -tulosraportti
77 päivää sitten
‧46 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 823 | - | - | ||
| 6 909 | - | - | ||
| 7 | - | - | ||
| 183 | - | - | ||
| 817 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 293 982 | 1 293 982 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 293 982 | 1 293 982 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 min sittenThe situation and going forward In biotech companies, it is often observed that the share price continues to trade weakly during the subscription period itself, especially when the issue is made with such a large discount as in this case, approximately 34 percent against TERP. One reason is that guarantee consortia and arbitrage trading can create additional selling pressure in the share. At the same time, the market usually interprets the situation as the company having now secured its financing, but that it needed to offer very attractive terms to successfully raise the capital. A discount of 34 % is quite aggressive but not uncommon in smaller biotech companies with high risk. This usually signals that the company has prioritized securing capital quickly over protecting the share price level. How the share develops after the issue is often determined by several factors. Investors look closely at how much has been subscribed by existing owners compared to guarantors, and how long the new capital is expected to last. When larger owners and management participate heavily in the issue, it is usually seen as a sign of strength, while it is often perceived more negatively if the guarantors are forced to take a large share. For Oncopeptides, the market will likely focus on the company's cash runway after the issue, the development in sales, and whether the capital raise is deemed sufficient for a longer period or just a temporary solution before further financing is needed. "In connection with the Rights Issue, the Company has entered into a lock-up undertaking, with customary exceptions, according to which the Company's board of directors may not propose or resolve on any new issue during a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided however that the Company has the right to issue and transfer warrants to the European Investment Bank (EIB) (in accordance with the agreement previously entered into between the Company and the EIB). Furthermore, the board members and senior executives of Oncopeptides have undertaken not to sell any shares in Oncopeptides during a period of 180 calendar days after the announcement of the result of the Rights Issue, subject to customary exceptions." In many similar biotech cases, one therefore sees a relatively weak or sluggish share price development during and after the issue period, where the share sometimes reaches a bottom after the subscription period. Thereafter, the share price can either recover in a relief rally when uncertainty decreases, or continue downwards if the market believes that the company will need to raise more capital later on. Next week?- ·4 t sitten · Muokattu·3 t sittenI believe Italy and Austria will grow. Germany provides a stable contribution and will grow in H2 (due to Marina). Spain will not be as bad as one might fear.
·3 t sittenExciting! I was actually of a similar opinion, so let's cross our fingers. - ·2 päivää sittenAnalysts have updated the target price 2026-04-28
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
77 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 min sittenThe situation and going forward In biotech companies, it is often observed that the share price continues to trade weakly during the subscription period itself, especially when the issue is made with such a large discount as in this case, approximately 34 percent against TERP. One reason is that guarantee consortia and arbitrage trading can create additional selling pressure in the share. At the same time, the market usually interprets the situation as the company having now secured its financing, but that it needed to offer very attractive terms to successfully raise the capital. A discount of 34 % is quite aggressive but not uncommon in smaller biotech companies with high risk. This usually signals that the company has prioritized securing capital quickly over protecting the share price level. How the share develops after the issue is often determined by several factors. Investors look closely at how much has been subscribed by existing owners compared to guarantors, and how long the new capital is expected to last. When larger owners and management participate heavily in the issue, it is usually seen as a sign of strength, while it is often perceived more negatively if the guarantors are forced to take a large share. For Oncopeptides, the market will likely focus on the company's cash runway after the issue, the development in sales, and whether the capital raise is deemed sufficient for a longer period or just a temporary solution before further financing is needed. "In connection with the Rights Issue, the Company has entered into a lock-up undertaking, with customary exceptions, according to which the Company's board of directors may not propose or resolve on any new issue during a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided however that the Company has the right to issue and transfer warrants to the European Investment Bank (EIB) (in accordance with the agreement previously entered into between the Company and the EIB). Furthermore, the board members and senior executives of Oncopeptides have undertaken not to sell any shares in Oncopeptides during a period of 180 calendar days after the announcement of the result of the Rights Issue, subject to customary exceptions." In many similar biotech cases, one therefore sees a relatively weak or sluggish share price development during and after the issue period, where the share sometimes reaches a bottom after the subscription period. Thereafter, the share price can either recover in a relief rally when uncertainty decreases, or continue downwards if the market believes that the company will need to raise more capital later on. Next week?
- ·4 t sitten · Muokattu·3 t sittenI believe Italy and Austria will grow. Germany provides a stable contribution and will grow in H2 (due to Marina). Spain will not be as bad as one might fear.·3 t sittenExciting! I was actually of a similar opinion, so let's cross our fingers.
- ·2 päivää sittenAnalysts have updated the target price 2026-04-28
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 823 | - | - | ||
| 6 909 | - | - | ||
| 7 | - | - | ||
| 183 | - | - | ||
| 817 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 293 982 | 1 293 982 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 293 982 | 1 293 982 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
77 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 min sittenThe situation and going forward In biotech companies, it is often observed that the share price continues to trade weakly during the subscription period itself, especially when the issue is made with such a large discount as in this case, approximately 34 percent against TERP. One reason is that guarantee consortia and arbitrage trading can create additional selling pressure in the share. At the same time, the market usually interprets the situation as the company having now secured its financing, but that it needed to offer very attractive terms to successfully raise the capital. A discount of 34 % is quite aggressive but not uncommon in smaller biotech companies with high risk. This usually signals that the company has prioritized securing capital quickly over protecting the share price level. How the share develops after the issue is often determined by several factors. Investors look closely at how much has been subscribed by existing owners compared to guarantors, and how long the new capital is expected to last. When larger owners and management participate heavily in the issue, it is usually seen as a sign of strength, while it is often perceived more negatively if the guarantors are forced to take a large share. For Oncopeptides, the market will likely focus on the company's cash runway after the issue, the development in sales, and whether the capital raise is deemed sufficient for a longer period or just a temporary solution before further financing is needed. "In connection with the Rights Issue, the Company has entered into a lock-up undertaking, with customary exceptions, according to which the Company's board of directors may not propose or resolve on any new issue during a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided however that the Company has the right to issue and transfer warrants to the European Investment Bank (EIB) (in accordance with the agreement previously entered into between the Company and the EIB). Furthermore, the board members and senior executives of Oncopeptides have undertaken not to sell any shares in Oncopeptides during a period of 180 calendar days after the announcement of the result of the Rights Issue, subject to customary exceptions." In many similar biotech cases, one therefore sees a relatively weak or sluggish share price development during and after the issue period, where the share sometimes reaches a bottom after the subscription period. Thereafter, the share price can either recover in a relief rally when uncertainty decreases, or continue downwards if the market believes that the company will need to raise more capital later on. Next week?
- ·4 t sitten · Muokattu·3 t sittenI believe Italy and Austria will grow. Germany provides a stable contribution and will grow in H2 (due to Marina). Spain will not be as bad as one might fear.·3 t sittenExciting! I was actually of a similar opinion, so let's cross our fingers.
- ·2 päivää sittenAnalysts have updated the target price 2026-04-28
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 823 | - | - | ||
| 6 909 | - | - | ||
| 7 | - | - | ||
| 183 | - | - | ||
| 817 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 293 982 | 1 293 982 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 293 982 | 1 293 982 | 0 | 0 |